An investor in AbbVie Inc. has sued the pharmaceutical company in Delaware Chancery Court to investigate an alleged kickback scheme that boosted sales of its popular immunosuppressant Humira and potentially exposed the company to more than $6 billion in legal liability.

The 28-page filing, filed May 3, claimed that senior officers and directors had allowed the firm to illegally promote Humira, which is used to treat rheumatoid arthritis, Crohn’s disease and other inflammatory conditions, by offering doctors benefits in exchange for prescribing the drug.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]